Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion's current focus is the development of a programmable—and therefore intelligent—platform capable of delivering chemotherapeutic drugs directly to cancer cells, thereby improving efficacy while reducing the toxic side effects associated with current chemotherapy treatment regimes. Underlying this platform is the use of genetically engineered non-living bacterial minicells that provide a multitude of comparative advantages over alternative bacterial and liposomal drug-delivery systems. Vaxiion's proprietary minicell-based drug delivery system, which is protected by a robust intellectual property estate, has shown compelling efficacy in preclinical animal models.